Cancer Medicines Forum: June 2025

• Date:
  Tuesday, 17 June 2025 , 14:00 - 17:00 Amsterdam time (CEST)
• Location:
  Online
  European Medicines Agency, Amsterdam, the Netherlands

Event summary

Setting up in March 2022, the Cancer Medicines Forum (CMF) was created by EMA in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) with the overall goal to optimise cancer treatments.

During the June 2025 meeting, the following topics were discussed:

• The EMA provided an overview on the concern that the safety data collection through the Common Terminology Criteria for Adverse Events (CTCAE) reporting system may not sufficiently capture the information required to support clinical decision-making.
• The EMA provided an overview of the work developed by the Cancer Immunotherapy Adverse Events Working Group, composed of international clinicians, researchers, methodologists, and biostatisticians, outlining the current challenges in the reporting and analysis of adverse events (AEs) in clinical trials.
• The EORTC presented a bladder cancer trial aiming to optimise treatment duration, exploring risk-proportional trial designs and innovative funding models.
• The STARBURST platform seeks to refine response assessment in muscle-invasive bladder cancer to enable bladder-preserving strategies.
• Plans for the November 2025 CMF workshop were outlined, focusing on collaboration between industry and academia on treatment optimisation clinical trials.

Documents

Minutes of the Cancer Medicines Forum - June 2025